A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD

NCT05297292 | Unknown Phase 2 DMC

• 1 other identifier: MW02-2020-CP301
• Study Type: interventional
• Target: 433
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to compare the efficacy and safety of MW02 versus Lucentis in the treatment of neovascular age-related macular degeneration.The study was divided into two stages. The first stage was to explore the dose and the second stage was to explore the frequency of administration.

Conditions

Wet Age-related Macular Degeneration

Outcome Measures

Primary Outcomes (1)

• Change from Baseline in Best Corrected Visual Acuity (BCVA)

  Change from Baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study(ETDRS) letter score at week 52.

  At week 52

Secondary Outcomes (1)

• Change from Baseline in BCVA

  baseline to week 52

Study Arms (4)

Lucentis-0.5mg（Q4w）

ACTIVE COMPARATOR

It is administered once every 4 weeks for 48 weeks. Intravitreal injection was used, and the dose was 0.5mg.

Drug: Lucentis

MW02-1.0mg（Q4w）

EXPERIMENTAL

It is administered once every 4 weeks for 48 weeks. Intravitreal injection was used, and the dose was 1.0mg.

Drug: MW02

MW02-1.5mg（Q4w）

EXPERIMENTAL

It is administered once every 4 weeks for 48 weeks. Intravitreal injection was used, and the dose was 1.5mg.

Drug: MW02

MW02（Q8w）

EXPERIMENTAL

It is administered once every 4 weeks for 3 consecutive times, and then once every 8 weeks for 48 weeks.

Drug: MW02

Interventions

MW02 DRUG

MW02 is a recombinant anti-VEGF humanized monoclonal antibody injection.

MW02-1.0mg（Q4w）; MW02-1.5mg（Q4w）; MW02（Q8w）

Lucentis DRUG

a recombinant anti-VEGF humanized monoclonal antibody injection

Also known as: ranibizumab

Lucentis-0.5mg（Q4w）

Eligibility Criteria

• Age: 50 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• fully understand this research and sign ICF; Willing to follow and be able to complete all study procedures;
• Age ≥ 50 years old, \< 80 years old, male or female;
• Active CNV lesions in fovea and/or parafovea secondary to nAMD , which have not been treated in the study eye 3 months before screening;
• The BCVA of the study eye is 73\~24 letters (including boundary value), which is equivalent to 20/40 to 20/320 of Snellen's visual acuity chart.
• CNV area of the study eye≥50% of the total lesion area.

You may not qualify if:

• There is subretinal or intraretinal hemorrhage in the study eye, and the bleeding area is ≥ 50% of the total lesion area, or it is located in the fovea and the area is ≥ 1 optic disc area;
• The study eye has scar, fibrosis, geographic atrophy and dense hard exudation under the fovea.
• CNV caused by non-nAMD exists in the study eye (such as trauma, pathological myopia, multifocal choroiditis, ocular histoplasmosis, vascular stripes, etc.);
• The study eye has any eye diseases or medical history other than nAMD that may affect central vision and/or macular examine (diabetic retinopathy, retinal vein occlusion, retinal detachment, macular hole, macular epiretinal membrane, retinal pigment epithelium tear involving macular, vitreous macular traction syndrome, optic nerve disease, etc.);
• Intravitreous hemorrhage occurred in the study eye within 30 days before the first administration.
• The study eye has received the following intraocular surgery within 90 days, or has previously received various macular laser treatments (such as macular transposition, transpupillary thermotherapy, macular photocoagulation, vitrectomy, optic nerve incision, optic nerve sheath incision, etc.) (except those who have received Vitepofin-photodynamic therapy, cataract surgery and YAG posterior capsulotomy more than 3 months before screening) or have performed external eye surgery within 30 days;
• The study eye has used corticosteroids in the eye or in the whole body within 3 months or injected corticosteroids around the globe within 30 days before the first administration;
• The study eye has poorly controlled glaucoma (defined as intraocular pressure≥25 mmHg after anti-glaucoma treatment), and/or has received glaucoma filtering surgery (such as trabeculectomy, scleral bite, non-penetrating trabecular surgery, etc.);
• The study eye has high myopia with diopter≥8D
• The study eye has refractive interstitial turbidity and/or myosis that affect fundus or OCT examination;
• Aphakia (except intraocular lens) or rupture of posterior capsule of lens (except YAG laser posterior capsulotomy after intraocular lens implantation more than 30 days before the first administration);
• Scleromalacia exists in the study eye.

Sponsors & Collaborators

• Mabwell (Shanghai) Bioscience Co., Ltd.: lead

Study Sites (1)

West China Hospital of Sichuan University

Chengdu, Sichuan, China

RECRUITING

MeSH Terms

Interventions

Ranibizumab

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Central Study Contacts

ming zhang, professor

CONTACT

86+18980602122; Zhangming-yangcp@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 17, 2022
• First Posted: March 28, 2022
• Study Start: May 7, 2021
• Primary Completion: May 15, 2023
• Study Completion: June 30, 2024
• Last Updated: March 28, 2022

Record last verified: 2022-03

Locations

CN (1)